PDS Biotechnology to host KOL event on Versamune HPV

PDS Biotechnology (PDSB) will host a virtual key opinion leader event featuring Kevin Harrington and Katharine Price, to discuss the unmet need and current treatment landscape for recurrent/metastatic HPV16-positive HNSCC. The event will review the changing landscape of HNSCC in context with Merck’s KEYNOTE-689 study and the rapidly increasing incidences of HPV16-positive HNSCC in the US and Europe. The event will also include a review of Versamune HPV, which is currently being evaluated in a Phase 3 clinical trial in combination with pembrolizumab as a first-line treatment for R/M HPV16+ HNSCC, as well as in Phase 2 clinical trials for the treatment of various types of HPV16-positive cancers. Versamune HPV is a novel investigational human papilloma virus-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. The panel will discuss the emerging treatment landscape in 1L R/M HNSCC and the view of HPV-positive and HPV-negative HNSCC as two distinct diseases with different underlying causes, pathology, and contributions to the development of HNSCC, as well as identification and treatment of HPV16+ HNSCC.